Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Status:
Completed
Trial end date:
2017-08-07
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to
subjects with advanced solid tumors and recurrent malignant lymphoma. The study is designed
to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to
define a recommended Phase 2 dose of ARQ 092.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)